SIMONELLI, MATTEO
SIMONELLI, MATTEO
DIPARTIMENTO DI SCIENZE MEDICHE (attivo dal 01/01/2000 al 27/04/2012)
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas
2021 M. Rossi, L. Gay, F. Ambrogi, M.C. Nibali, T. Sciortino, G. Puglisi, A. Leonetti, C. Mocellini, M. Caroli, S. Cordera, M. Simonelli, F. Pessina, P. Navarria, A. Pace, R. Soffietti, R. Rudà, M. Riva, L. Bello
Correlation between activated infiltrating neutrophils and MGMT methylation in patients with diffuse malignant gliomas (MGs)
2018 M. Simonelli, M. Massara, P. Persico, A. Capucetti, E. Lorenzi, E. Lugli, A. Dipasquale, M. Nibali, M. Rossi, L. Bello, M. Locati, R. Bonecchi
Immunotherapeutic early-phase clinical trials and malignant gliomas : A single-center experience and comprehensive immunophenotyping of circulating leukocytes
2021 M. Simonelli, P. Persico, A. Capucetti, C. Carenza, S. Franzese, E. Lorenzi, A. Dipasquale, A. Losurdo, L. Giordano, F. Pessina, P. Navarria, L. Politi, D. Mavilio, M. Locati, S. Della Bella, A. Santoro, R. Bonecchi
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas
2010 P.A. Zucali, I. Petrini, E. Lorenzi, M. Merino, L. Cao, L. Di Tommaso, H.S. Lee, M. Incarbone, B.A. Walter, M. Simonelli, M. Roncalli, A. Santoro, G. Giaccone
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome
2019 M. Rossi, F. Ambrogi, L. Gay, M. Gallucci, M. Conti Nibali, A. Leonetti, G. Puglisi, T. Sciortino, H.R. Howells, M. Riva, F. Pessina, P. Navarria, C. Franzese, M. Simonelli, R. Rudà, L. Bello
Lower grade gliomas: relationships between metabolic and structural imaging with grading and molecular factors
2019 M. Riva, E. Lopci, A. Castellano, L. Olivari, M. Gallucci, F. Pessina, B. Fernandes, M. Simonelli, P. Navarria, M. Grimaldi, R. Rudà, A. Castello, M. Rossi, T. Alfiero, R. Soffietti, A. Chiti, L. Bello
Neutrophils in gliomas
2017 M. Massara, P. Persico, O. Bonavita, V. Mollica Poeta, M. Locati, M. Simonelli, R. Bonecchi
NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions
2021 V. Cazzetta, E. Bruni, S. Terzoli, C. Carenza, S. Franzese, R. Piazza, P. Marzano, M. Donadon, G. Torzilli, M. Cimino, M. Simonelli, L. Bello, A. Villa, L. Tan, S. Ravens, I. Prinz, D. Supino, F.S. Colombo, E. Lugli, E. Marcenaro, E. Vivier, S. Della Bella, J. Mikulak, D. Mavilio
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma
2016 M. Simonelli, P. Zucali, A. Santoro, M.B. Thomas, F.G. de Braud, H. Borghaei, J. Berlin, C.S. Denlinger, C. Noberasco, L. Rimassa, T. Kim, P.A. English, A. Abbattista, C. Gallo Stampino, M. Carpentieri, J.A. Williams
Role of myeloid cells in the immunosuppressive microenvironment in gliomas
2020 C.V. Locarno, M. Simonelli, C. Carenza, A. Capucetti, E. Stanzani, E. Lorenzi, P. Persico, S. Della Bella, L. Passoni, D. Mavilio, R. Bonecchi, M. Locati, B. Savino
Tivantinib : a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma
2013 L. Rimassa, N. Personeni, M. Simonelli, A. Santoro